LCZ696(Sacubitril + Valsartan)

Kufotokozera Kwachidule:

Dzina la API Chizindikiro Kufotokozera US DMF EU DMF CEP
LCZ696(Sacubitril + Valsartan) Kulephera kwa mtima M'nyumba    


Tsatanetsatane wa Zamalonda

Zolemba Zamalonda

PRODUCT DETAIL

Kufotokozera

LCZ696 (Sacubitril/Valsartan), yopangidwa ndi Valsartan (an ARB) ndi Sacubitril (AHU377) mu 1: 1 molar ratio, ndi yoyamba mu kalasi, pakamwa bioavailable, ndi awiri-acting angiotensin receptor-neprilysin (ARN) inhibitor kwa hypertension. ndi kulephera kwa mtima [1] [2] [3].LCZ696 imathandizira matenda a shuga a cardiomyopathy poletsa kutupa, kupsinjika kwa okosijeni ndi apoptosis.

 

Mbiri

LCZ696 ndi yoyamba m'kalasi ya ARNi (angiotensin receptor neprilysin inhibitor) yomwe imakhala ndi anionic moieties ya AR valsartan ndi neprilysin inhibitor prodrug AHU377 (1: 1 chiŵerengero) cha kulephera kwa mtima ndi matenda oopsa.

Ma angiotensin receptors ndi ma G-protein-coupled receptors.Amayimira pakati pamtima ndi zotsatira zina za angiotensin II yomwe ndi bioactive peptide ya renin-angiotensin system.Neprilysin ndi endopeptidase yopanda ndale yomwe imawononga ma peptides amkati a vasoactive monga natriuretic peptides.Kuletsa kwa neprilysin kumawonjezera kuchuluka kwa ma peptides a natriuretic omwe amathandizira pakuteteza mtima, mitsempha ndi aimpso.[1]

Mu makoswe a Sprague-Dawley, kuwongolera pakamwa kwa LCZ696 kunapangitsa kuti pakhale kukwera kodalira kwa mlingo wa immunoreactivity wa peptide ya atrial natriuretic chifukwa cha kuletsa kwa neprilysin.Mu makoswe amtundu wapawiri wa transgenic, LCZ696 idapangitsa kudalira kwa mlingo komanso kuchepetsedwa kosalekeza kwa kupanikizika kwapakati.Ophunzira athanzi, kafukufuku wopangidwa mwachisawawa, wakhungu kawiri, woyendetsedwa ndi placebo adatsimikizira kuti LCZ696 idapereka inhibition ya neprilysin inhibition ndi AT1 receptor blockade.LCZ696 inali yotetezeka komanso yololera mwa anthu.[2] [3]

Zolozera:
McMurray JJ, Packer M, Desai AS et al.Angiotensin-neprilysin inhibition motsutsana ndi enalapril mu kulephera kwa mtima.N Engl J Med.2014 Sep 11; 371(11): 993-1004.
Gu J, Noe A, Chandra P, Al-Fayoumi S et al.Pharmacokinetics ndi pharmacodynamics ya LCZ696, novel-acting angiotensin receptor-neprilysin inhibitor (ARNi).J Clin Pharmacol.2010 Apr;50(4):401-14.
Langenickel TH, Dole WP.Angiotensin receptor-neprilysin inhibition ndi LCZ696: njira yatsopano yochizira kulephera kwa mtima, Drug Discov Today: Ther Strategies (2014),

 

Kusungirako

Ufa

-20 ° C

3 zaka
 

4°C

zaka 2
Mu zosungunulira

-80 ° C

6 miyezi
 

-20 ° C

1 mwezi

Kapangidwe ka mankhwala

LCZ696(Sacubitril + Valsartan)

CERTIFICATE

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

KUSINTHA KWA KHALIDWE

Quality management1

Malingaliro18Ma projekiti a Quality Consistency Evaluation omwe avomereza4,ndi6mapulojekiti akuvomerezedwa.

Quality management2

Njira zotsogola zapadziko lonse lapansi zoyendetsera bwino zakhazikitsa maziko olimba pakugulitsa.

Quality management3

Kuyang'anira kwabwino kumayendera nthawi yonse ya moyo wa chinthucho kuti zitsimikizire kuti zabwino ndi zochiritsira.

Quality management4

Gulu la Professional Regulatory Affairs limathandizira zofunikira pakufunsira ndikulembetsa.

MANAGEMENT ZOPHUNZITSA

cpf5
cpf6

Korea Countec Bottled Packaging Line

cpf7
cpf8

Taiwan CVC Bottled Packaging Line

cpf9
cpf10

Italy CAM Board Packaging Line

cpf11

German Fette Compacting Machine

cpf12

Japan Viswill Tablet Detector

cpf14-1

Chipinda chowongolera cha DCS

WOTHANDIZA

Mgwirizano wapadziko lonse lapansi
International cooperation
Mgwirizano wapakhomo
Domestic cooperation

  • Zam'mbuyo:
  • Ena:

  • Lembani uthenga wanu apa ndikutumiza kwa ife